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The estimated glomerular filtration rate (eGFR) is a powerful
predictor of adverse outcomes, but most attention has
focused on studies in the setting of reduced eGFR.
Here we tested whether patients with an eGFR higher than
60–89.9ml/min per 1.73m2 could also be at elevated risk of
adverse outcomes. Further, we tested whether concomitant
proteinuria further increases the risk of outcomes among
individuals with an eGFR equal to or above 90ml/min per
1.73m2, as it does for those with reduced eGFR. Using data
from a population-based outpatient laboratory data set
of 1,526,437 patients, we measured adjusted associations
between eGFR calculated by the modification of diet in renal
disease equation, urine dipstick proteinuria, and adverse
clinical outcomes. The adjusted risk of all-cause mortality was
lowest at an eGFR of 60–74.9ml/min per 1.73m2 (referent)
and increased at both lower and higher levels of eGFR.
Specifically, the hazard ratio of death was 3.7 and 1.8 among
patients with an eGFR equal to or above 105 and
90–104.9ml/min per 1.73m2, respectively, compared to the
referent group. Similar results were seen when the CKD-EPI
equation (sensitivity analyses) was used to assess eGFR.
Higher levels of eGFR were not associated with the risk of
kidney failure or myocardial infarction. Thus, the presence
and severity of proteinuria was significantly associated with
graded increases in the risk of clinical outcomes for both
lower and higher eGFR. We do not know, however, whether
the finding at higher eGFR could be due to inadequacies of
the eGFR formula at low serum creatinine levels.
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Chronic kidney disease (CKD) is a major public health
problem in both developed and developing countries. A large
body of literature demonstrates that estimated glomerular
filtration rate (eGFR) is a powerful predictor of adverse
clinical outcomes such as all-cause mortality, progression to
kidney failure, and cardiovascular events. However, most
studies have focused on people with reduced eGFR—which is
a cardinal manifestation of CKD, and may be used in
conjunction with measurements of proteinuria to identify
people at higher risk of adverse outcomes.1
Among people with diabetes, higher levels of eGFR
correlate with the presence of hyperfiltration, a pathophy-
siological stage of diabetic nephropathy that is associated
with incipient loss of kidney function.2 Whether higher eGFR
is associated with adverse clinical outcomes independently of
diabetic status is less well documented, although a recent
cohort study suggested that mortality was increased in people
with eGFR X105ml/min per 1.73m2, as compared with
those with eGFR of 60–89.9ml/min per 1.73m2.3
We studied a large cohort of people receiving
routine clinical care in a single Canadian province, in
which all residents are covered by government-sponsored
health insurance. We examined the association between
eGFR, proteinuria, and adverse clinical outcomes including
all-cause mortality, myocardial infarction, and progression to
kidney failure. We hypothesized that (independent of diabetic
status) patients with both higher and lower levels of eGFR
would be at higher risk of these outcomes than participants
with eGFR of 60–89.9ml/min per 1.73m2. We also hypothe-
sized that the presence of proteinuria would increase the
risk of such outcomes among people with eGFRX90ml/min
per 1.73m2, as it does for those with eGFR o60ml/min
per 1.73m2.
RESULTS
Participant characteristics
A total of 1,530,447 participants had at least one outpatient
serum creatinine measurement during the study period. We
excluded 2345 people with end-stage renal disease before
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cohort entry and 1383 with index eGFR o15ml/min per
1.73m2. An additional 282 individuals were excluded because
they either died or reached end of follow-up on their index
date. Of the 1,526,437 participants, 920,985 (60.3%) had at
least one urine dipstick measurement. Characteristics of the
participants by level of eGFR and proteinuria are shown in
Table 1.
Follow-up and clinical outcomes
During median follow-up of 35 months (range 0–59 months),
27,959 (3.0%) of participants died, 5772 (0.6%) were hospi-
talized for myocardial infarction, 4692 (0.5%) were hospita-
lized for stroke or transient ischemic attack, 771 (0.08%)
initiated renal replacement therapy, 2514 (0.4%) experienced a
doubling of serum creatinine, and 726 (0.12%) experienced a
fourfold increase in serum creatinine. Within every stratum of
eGFR and proteinuria, participants who died were more likely
to be men, to be older, to have more comorbidity, and have
lower socioeconomic status than those who survived.
Adjusted likelihood of mortality and other adverse outcomes
by level of eGFR
The adjusted risk of all-cause mortality was lowest at eGFR of
60–74.9ml/min per 1.73m2, and was increased at lower and
higher levels of eGFR (Table 2). Results were similar among
participants with and without available proteinuria measure-
ments and after the exclusion of participants with diabetes at
baseline (data not shown). The U-shaped relation between
mortality and eGFR appeared to be independent of age, as an
increased risk of death was observed in participants with
eGFR 4105ml/min per 1.73m2 (as compared with those
with 60–74.9ml/min per 1.73m2) in those aged o40 years
(hazard ratio (HR)¼ 1.9; 95% confidence interval (CI) 1.5,
2.4); 40–60 years (HR¼ 3.1; 95% CI 2.8, 3.5), and460 years
(HR 3.0; 95% CI 2.8, 3.3; Table 3). Findings were consistent
when the CKD-EPI equation was used instead of the
modification of diet in renal disease (MDRD) equation to
estimate eGFR (Figures 1 and 2).
Similar findings were observed for stroke/transient
ischemic attack, although the absolute magnitude of the
increase was substantially smaller and findings were of only
borderline statistical significance (Table 2). In contrast, the
adjusted risk of acute myocardial infarction progressively
declined at higher eGFR.
Adjusted likelihood of renal outcomes by level of eGFR
The adjusted risk of kidney failure treated with chronic
dialysis progressively decreased with increasing baseline
kidney function (Table 4). However, the adjusted likelihood
of experiencing a doubling of serum creatinine was lowest at
Table 1 | Demographic and clinical characteristics of participants, by level of kidney function or proteinuria
N=920,985
eGFR (ml/min per 1.73m2)a Proteinuria measured by dipstick
X105
(N=66,146)
90–104.9
(N=156,555)
75–89.9
(N=323,534)
60–74.9
(N=274,336)
45–59.9
(N=79,845)
30–44.9
(N=16,713)
15–29.9
(N=3,856)
None
(N=836,550)
Mild
(N=71,557)
Heavy
(N=12,878)
Age (years)b 34.1 (13.1) 39.1 (13.8) 45.8 (14.0) 54.3 (14.2) 65.8 (14.0) 75.1 (12.2) 74.7 (13.9) 48.4 (16.3) 50.8 (19.7) 55.4 (20.3)
Female 61 54 53 56 64 65 61 56 52 44
Aboriginal 6 3 2 1 1 1 2 2 4 4
Diabetes 6 5 5 7 13 25 36 6 14 31
Hypertension 8 11 16 27 49 76 82 21 32 50
Cerebrovascular disease 1 1 1 2 6 12 15 2 4 8
Peripheral vascular disease 1 1 1 1 4 9 14 1 3 6
CHF 1 1 1 1 7 20 33 2 5 11
Cancer 3 3 3 5 8 13 16 4 7 10
COPD 13 13 13 14 18 25 30 13 18 21
Dementia 0 0 0 1 3 8 11 1 3 4
Complicated diabetes 0 0 0 0 1 5 11 0 1 6
Uncomplicated diabetes 3 2 2 3 7 15 26 3 7 18
AIDS/HIV 0 0 0 0 0 0 0 0 0 0
Metastatic solid tumor 1 0 0 1 1 2 3 0 1 2
Myocardial infarction 1 1 1 2 5 12 18 2 4 8
Mild liver disease 2 1 1 1 1 2 2 1 2 2
Liver disease 0 0 0 0 0 0 1 0 0 0
Paralysis 1 0 0 0 1 1 2 0 1 1
Peptic ulcer disease 2 2 2 2 3 5 7 2 3 4
Renal disease 0 0 0 0 3 18 52 1 3 14
Rheumatic disease 1 1 1 1 2 4 5 1 2 3
Socioeconomic status
Low 15 13 14 19 38 60 60 18 25 33
Low with subsidy 5 3 2 2 2 2 3 2 4 4
Abbreviations: AIDS, acquired immunodeficiency syndrome; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration
rate; HIV, human immunodeficiency virus.
aAmong patients with proteinuria measured by dipstick.
bData expressed as %, except mean (standard deviation). Totals do not always add to 100% because of rounding. Socioeconomic status was categorized as high (annual
adjusted taxable family income X$39,250 CAD), low (annual adjusted taxable family income o$39,250 CAD), and low with subsidy (receiving social assistance) based on
government of Alberta health care insurance records.28
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baseline eGFR of 60–90ml/min per 1.73m2, and was increased
at higher and lower eGFR. Although the adjusted likelihood of
fourfold increases in serum creatinine was also increased at
higher and lower eGFR, the magnitude of the excess risk at
higher eGFR was smaller, suggesting that regression to the
mean might partially account for the findings.
Modification of risk by proteinuria
Within all strata of eGFR, there was substantial variability in
risk with participants who had heavier proteinuria, demon-
strating markedly increased risk of all six adverse outcomes
(Tables 2–4). In fact, the risk of adverse clinical outcomes was
increased by 633% for all-cause mortality, 208% for stroke,
283% for end-stage renal disease, and 33% for acute
myocardial infarction among participants with the highest
baseline eGFR (X105ml/min per 1.73m2) and heavy
proteinuria, as compared with participants with reduced
eGFR between 45 and 59.9ml/min per 1.73m2 and no
proteinuria.
Significant interactions between eGFR and proteinuria
were observed for death, initiation of renal replacement, and
doubling of serum creatinine—such that the additional risk
of heavier proteinuria was reduced at lower eGFR (all P for
interaction statistically significant at o0.01)—but not for
myocardial infarction (P for interaction 0.24) or stroke
(P for interaction 0.67). Although statistically significant,
these interactions did not appear clinically relevant, as the
difference in risk associated with heavy proteinuria (as
compared to those without proteinuria) was readily appa-
rent within every eGFR stratum, and for all six clinical
outcomes.
DISCUSSION
This study of more than 900,000 people treated in a single
Canadian province has three key findings. First, the adjusted
risks of all-cause mortality and cerebrovascular events were
increased at both higher and lower levels of eGFR, as
compared with intermediate levels of eGFR (60–74.9ml/min
per 1.73m2). In fact, the magnitude of the excess risk for
death associated with the highest levels of eGFR (X105ml/
min per 1.73m2) was comparable to that associated with the
lowest levels (15–29.9ml/min per 1.73m2). The relative
increase in the risk of death associated with higher eGFR
was more pronounced in older individuals than for younger
individuals (for example, compared with eGFR of 60–74.9ml/
min per 1.73m2, the hazard ratio of eGFR4105ml/min per
1.73m2 was 3.0 (95% CI 2.8, 3.3) for people aged 460 and
1.9 (95% CI 1.5, 2.4) for people agedo40 years). Second, the
adjusted risk of doubling of serum creatinine was increased
at higher levels of eGFR than at intermediate levels—but the
Table 2 | Adjusted hazard ratios of clinical outcomes, by level of eGFR and proteinuria
All-cause mortality Acute myocardial infarction Stroke or transient ischemic attack
Proteinuria
by dipstick Normal Mild Heavy Overall Normal Mild Heavy Overall Normal Mild Heavy Overall
eGFR
X105
HR 3.6 7.5 8.8 3.7 0.8 0.9 1.6 0.8 1.2 1.7 3.7 1.2
95% CI (3.4, 3.9) (6.8, 8.3) (7.0, 11.0) (3.5, 3.9) (0.6, 1.0) (0.5, 1.6) (0.7, 3.9) (0.6, 1.0) (0.9, 1.5) (1.0, 2.9) (1.8, 7.8) (1.0, 1.5)
90–104.9
HR 1.8 3.6 4.9 1.8 0.8 1.1 1.9 0.8 1.2 1.3 3.9 1.1
95% CI (1.7, 1.9) (3.3, 4.0) (4.0, 6.0) (1.7, 1.9) (0.7, 1.0) (0.8, 1.5) (1.1, 3.3) (0.7, 0.9) (1.0, 1.3) (0.9, 1.9) (2.3, 6.5) (1.0, 1.3)
75–89.9
HR 1.2 2.4 2.8 1.2 0.9 1.4 1.6 0.9 1.0 1.4 2.2 1.0
95% CI (1.1, 1.2) (2.3, 2.6) (2.4, 3.2) (1.1, 1.2) (0.8, 1.0) (1.2, 1.6) (1.1, 2.2) (0.9, 1.0) (0.9, 1.1) (1.2, 1.8) (1.5, 3.2) (0.9, 1.0)
60–74.9
HR 1 2.0 2.7 1 1 1.4 1.6 1 1 1.5 2.3 1
95% CI (1.9, 2.2) (2.5, 3.0) (1.2, 1.6) (1.2, 2.1) (1.3, 1.8) (1.8, 3.0)
45–59.9
HR 1.2 2.2 3.1 1.2 1.2 1.3 1.8 1.2 1.2 1.5 2.3 1.2
95% CI (1.2, 1.3) (2.1, 2.3) (2.8, 3.4) (1.2, 1.3) (1.1, 1.3) (1.1, 1.5) (1.4, 2.3) (1.1, 1.2) (1.1, 1.3) (1.3, 1.8) (1.8, 2.9) (1.1, 1.2)
30–44.9
HR 1.6 2.4 3.2 1.6 1.4 1.5 2.1 1.4 1.2 1.8 2.5 1.3
95% CI (1.6, 1.7) (2.3, 2.6) (2.9, 3.5) (1.6, 1.7) (1.3, 1.6) (1.2, 1.8) (1.6, 2.6) (1.3, 1.6) (1.1, 1.4) (1.5, 2.2) (2.0, 3.2) (1.2, 1.5)
15–29.9
HR 2.8 3.8 4.5 2.7 2.0 2.1 3.1 2.1 1.4 1.6 2.4 1.4
95% CI (2.6, 3.0) (3.5, 4.2) (4.1, 5.0) (2.6, 2.9) (1.6, 2.5) (1.6, 2.8) (2.4, 4.1) (1.8, 2.5) (1.0, 1.8) (1.2, 2.3) (1.7, 3.3) (1.2, 1.7)
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate estimated by modification of diet in renal disease equation; HR, hazard ratio.
Adjusted for: age, sex, diabetes, hypertension, socioeconomic status, and history of cancer, cerebrovascular disease, congestive heart failure, chronic pulmonary disease,
dementia, diabetes with end-organ damage, diabetes without chronic complication, AIDS/HIV, metastatic solid tumor, myocardial infarction, mild liver disease, moderate or
severe liver disease, paralysis, peptic ulcer disease, peripheral vascular disease, or rheumatic disease.
For analyses using dipstick urinalysis to classify participants with respect to proteinuria, categories were: normal (urine dipstick negative); mild (urine dipstick trace or 1+) or
heavy (urine dipstick X2+). N=920,985.
Each cell presents the adjusted hazard ratio (expressed in bold font), and its 95% CI. The referent category is the intersection category of eGFR 60–74.9 and normal proteinuria.
For the overall results (shaded in gray), the referent category is eGFR 60–74.9.
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risk of a more clinically relevant renal outcome (initiation of
chronic dialysis) was not. Third, regardless of baseline eGFR
(low, intermediate, or high), heavier levels of proteinuria
were strongly and independently associated with worse
clinical outcomes.
Why were higher levels of eGFR associated with excess
mortality? The lack of association between myocardial
infarction and higher eGFR levels seems to argue against
vascular causes as the sole explanation—especially given the
modest increase in the risk of cerebrovascular disease at
higher eGFR, which was not observed in people without
heavy proteinuria and was of only borderline significance. As
we adjusted for diabetes status (and excluded people with
known diabetes in sensitivity analysis), diagnosed diabetes is
not the explanation for our findings. Although incipient
(undiagnosed) diabetes might partially account for higher
mortality at higher eGFR, the magnitude of the association
argues against this as the sole explanation.
It is important to recognize that higher eGFR may not
correspond to higher true eGFR. As higher eGFR correlates
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Figure 1 |Risk of all-cause mortality, by estimated glomerular
filtration rate (eGFR) using the MDRD equation (N¼ 920,985).
Proteinuria assessed by dipstick urinalysis. This model is fully
adjusted for age, sex, diabetes, hypertension, socioeconomic
status, and history of cancer, cerebrovascular disease, congestive
heart failure, chronic pulmonary disease, dementia, diabetes
with end-organ damage, diabetes without chronic complication,
AIDS/HIV, metastatic solid tumor, myocardial infarction, mild liver
disease, moderate or severe liver disease, paralysis, peptic ulcer
disease, peripheral vascular disease, or rheumatic disease. The
relative increase in the risk of death associated with higher eGFR
was more pronounced in older individuals than for younger
individuals (e.g., compared with eGFR of 60–74.9ml/min per
1.73m2, the hazard ratio of eGFR4105ml/min per 1.73m2 was 3.0
(95% confidence interval (CI) 2.8, 3.3) for people aged 460 and
1.9 (95% CI 1.5, 2.4) for people aged o40 years). MDRD,
modification of diet in renal disease equation.
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Figure 2 |Risk of all-cause mortality, by estimated
glomerular filtration rate (eGFR) using the CKD-EPI equation
(N¼ 920,908). Proteinuria assessed by dipstick urinalysis.
This model is fully adjusted for age, sex, diabetes, hypertension,
socioeconomic status, and history of cancer, cerebrovascular
disease, congestive heart failure, chronic pulmonary disease,
dementia, diabetes with end-organ damage, diabetes without
chronic complication, AIDS/HIV, metastatic solid tumor,
myocardial infarction, mild liver disease, moderate or severe liver
disease, paralysis, peptic ulcer disease, peripheral vascular disease,
or rheumatic disease. The relative increase in the risk of death
associated with higher eGFR was more pronounced in older
individuals than for younger individuals (e.g., compared with
eGFR of 60–74.9ml/min per 1.73m2, the hazard ratio of
eGFR4105ml/min per 1.73m2 was 5.3 (95% confidence interval
(CI) 4.3, 6.5) for people aged 460 and 1.1 (95% CI 0.8, 1.6) for
people aged o40 years). CKD, chronic kidney disease.
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with lower serum creatinine values and with lower muscle
mass,4 it is possible that malnutrition/low body mass index,
inflammation, differences in body composition, or undiag-
nosed malignancy account for the excess mortality in this
group. Although the magnitude of the association between
higher eGFR and mortality became even stronger after
adjustment for measured comorbidity, we cannot exclude the
possibility that our findings were influenced by residual
confounding—or inaccurate estimates of eGFR at very low
levels of serum creatinine. Therefore, our data do not allow
us to confirm or refute these speculations, especially as we
did not have data on the cause of death. Even if the apparent
link between high eGFR and adverse outcomes is not causal,
recognition of this association might prove clinically useful—
as is the case for other clinical parameters with prognostic
power, such as low serum albumin or hemoglobin.
We found that people with higher baseline levels of eGFR
were more likely to experience a doubling of serum creatinine
during follow-up. Although this observation might represent
more rapid progression of early kidney disease in this
population, the risk of chronic dialysis treatment was
inversely associated with eGFR—with no excess risk seen at
higher baseline levels. Therefore, a more plausible explana-
tion for the apparently increased likelihood of twofold
increases in serum creatinine may be regression to the
mean—especially as the excess risk of fourfold increases in
serum creatinine among people with higher baseline eGFR was
much more modest than the excess risk of twofold increases.
However, studies with longer follow-up will be required to
conclusively exclude a true association between risk of
developing kidney failure and higher baseline levels of eGFR.
Previous work examining the association between higher
levels of eGFR and adverse outcomes has primarily been
conducted in people with diabetes. A Finnish study of 4201
people with type 1 diabetes also reported an increased risk of
mortality at lower and higher eGFR, with lowest predicted
mortality when eGFR was B70–80ml/min per 1.73m2,5 and
attributed the excess risk to incipient microalbuminuria6—
itself associated with adverse events.7 Other studies have
linked higher levels of eGFR to an increased risk of
developing microalbuminuria or progressive loss of kidney
function in people with type 2 diabetes,8,9 although not all
authors have confirmed these findings.10 Data from non-
diabetic populations are more limited. A large meta-analysis
of seven previous studies with more than 1.1 million
participants found a similar increase in the relative risk of
all-cause and cardiovascular death at higher eGFR, although
absolute risks and the risks of individual cardiovascular or
renal events were not reported.11 A smaller (N¼ 252,516, of
whom 10% had diabetes) study from our group examined
the risk of pneumonia and its consequences among people
with CKD, and also found higher mortality at levels of eGFR
Table 4 | Adjusted hazard ratios of renal outcomes, by level of eGFR and proteinuria
ESRD Doubling of serum creatinine Fourfold increase in serum creatinine
Proteinuria
by dipstick Normal Mild Heavy Overall Normal Mild Heavy Overall Normal Mild Heavy Overall
eGFR
X105
HR 0.4 1.0 18 0.3 5.8 8.2 33 4.2 1.8 3.7 31 1.6
95% CI (0.1, 1.3) (0.2, 4.9) (5.5, 61) (0.1, 0.8) (4.6, 7.2) (5.5, 12.4) (20, 52) (3.5, 5.1) (0.9, 3.3) (1.3, 10.1) (13.3, 72) (1.0, 2.5)
90–104.9
HR 0.8 1.2 8.3 0.5 1.8 3.6 13 1.4 1.7 4.2 19.7 1.4
95% CI (0.4, 1.6) (0.3, 5.0) (2.0, 35) (0.3, 0.8) (1.4, 2.2) (2.4, 5.4) (8, 22) (1.2, 1.7) (1.1, 2.6) (2.2, 8.2) (9.0, 43) (1.0, 2.0)
75–89.9
HR 0.6 1.0 37 0.5 1.1 2.9 13 1.0 1.1 2.4 16.1 1.0
95% CI (0.3, 1.0) (0.3, 3.4) (19, 71) (0.4, 0.8) (1.0, 1.3) (2.2, 3.8) (10, 18) (0.9, 1.2) (0.8, 1.5) (1.4, 4.2) (9.3, 27.7) (0.7, 1.2)
60–74.9
HR 1 2.5 38 1 1 3.2 11 1 1 3.5 11.1 1
95% CI (1.0, 6.2) (21, 74) (2.6, 4.0) (9, 15) (2.3, 5.3) (6.6, 19.1)
45–59.9
HR 4.7 22 132 7.8 1.8 3.8 20 1.9 1.6 5.4 40 2.5
95% CI (2.7, 8.1) (12, 40) (79, 221) (5.4, 11.2) (1.5, 2.1) (3.1, 4.9) (16, 25) (1.7, 2.2) (1.1, 2.2) (3.6, 8.2) (28, 56) (2.0, 3.2)
30–44.9
HR 40 140 561 80 3.7 8.5 26 4.5 4.0 15.8 51 7.3
95% CI (24, 69) (84, 235) (354, 880) (56, 112) (3.0, 4.5) (6.8, 10.5) (21, 32) (3.9, 5.2) (2.7, 6.0) (10.9, 22.9) (36, 72) (5.7, 9.4)
15–29.9
HR 478 1022 2752 706 8.7 22 53 13.9 8.5 28.8 63 16.3
95% CI (296, 781) (646, 1636) (1790, 4273) (508, 992) (6.7, 11.4) (17, 28) (44, 64) (11.9, 16.1) (4.8, 15.3) (18.2, 45.6) (44, 91) (12.2, 21.8)
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
eGFR is estimated by modification of diet in renal disease equation.
Adjusted for: age, sex, diabetes, hypertension, socioeconomic status, and history of cancer, cerebrovascular disease, congestive heart failure, chronic pulmonary disease,
dementia, diabetes with end-organ damage, diabetes without chronic complication, AIDS/HIV, metastatic solid tumor, myocardial infarction, mild liver disease, moderate or
severe liver disease, paralysis, peptic ulcer disease, peripheral vascular disease, or rheumatic disease.
For analyses using dipstick urinalysis to classify participants with respect to proteinuria, categories were: normal (urine dipstick negative), mild (urine dipstick trace or 1+), or
heavy (urine dipstick X2+). N=920,985; N=620,231 for doubling of serum creatinine and fourfold increase in serum creatinine.
Each cell presents the adjusted hazard ratio (expressed in bold font), and its 95% CI. The referent category is the intersection category of eGFR 60–74.9 and normal
proteinuria. For the overall results (shaded in gray), the referent category is eGFR 60–74.
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4105ml/min per 1.73m2 (ref. 3), although cardiovascular
and renal outcomes were not assessed. The current manuscript
extends these findings to a broader range of adverse outcomes
in a large, community-based population, and describes the
incremental role of proteinuria at higher levels of eGFR.
Future work should replicate our analyses in representative
samples from the general population—especially in data sets
with greater detail on the baseline characteristics of people
with higher levels of eGFR and that include information on
cause-specific mortality. If confirmed, these findings have
implications for the interpretation of studies that report the
excess risk associated with reduced eGFR. Comparing people
with reduced eGFR to a referent category of460ml/min per
1.73m2 will tend to reduce the magnitude of the risk
attributed to lower eGFR—as compared with an alternative
referent category of 60–74ml/min per 1.73m2. Determination
of which referent group is more appropriate will require
further study. In addition, if our results are confirmed, this
might support the use of high eGFR for clinical risk
stratification, as has been proposed for low eGFR.12
Our study has limitations that should be considered when
interpreting results. First, all participants had an outpatient
serum creatinine measurement performed during clinical
encounters rather than in an epidemiological survey. As we
studied nearly one million subjects (and considering the
universal nature of health-care coverage in Alberta), this
limitation is unlikely to invalidate our findings. However,
readers should consider the possibility that people with high
eGFR in the current analysis may have characteristics
different from people with high eGFR in the general
population. Second, although we used all urine measure-
ments performed 6 months before and after the index eGFR
to classify our participants with respect to proteinuria, the
majority had only a single dipstick result, which may have led
to misclassification.13 However, better information on
proteinuria would be expected to increase the strength of
the observed associations. Third, we assessed the incidence of
doubling of serum creatinine during follow-up, which may
have included some participants with acute renal failure, as
well as those with progression of CKD or regression to the
mean. However, as we excluded in-patient measurements of
serum creatinine and acute renal failure in the community is
relatively infrequent,14 use of this outcome is unlikely to have
influenced our conclusions.15 Fourth, although we primarily
used the MDRD equation to estimate eGFR (which has well-
described limitations—especially at higher levels of kidney
function), results were consistent when the CKD-EPI
equation was used. Use of different biological markers (such
as serum cystatin)16 for estimating eGFR might partially
offset some of these disadvantages, although this suggestion
is speculative. Fifth, we did not have information on race
when using the eGFR estimating equations. However, as
o1% of the Alberta population is black, this should have had
minimal impact on our results. Sixth, the threshold values we
used to categorize higher levels of eGFR were arbitrarily
chosen, using increments of 15–30ml/min per 1.73m2
(similar to the existing system for categorizing lower eGFR).
Finally, in addition to the lack of data on markers of
inflammation and malnutrition, we did not have information
on other potential confounders such as the use of alcohol,
tobacco, and antihypertensive medications, which may have
resulted in residual confounding.
In conclusion, higher levels of eGFR were associated with
increased risk of all-cause mortality and cerebrovascular
events, especially when proteinuria was also present. This
might represent increases in risk at higher true eGFR,
inaccuracies in estimating true GFR at lower levels of
serum creatinine, or confounding by inflammation and
malnutrition. However, the findings have implications for
future studies and perhaps for risk stratification in clinical
practice.
MATERIALS AND METHODS
Study population and data sources
We used the Alberta Kidney Disease Network (AKDN) repository to
create the study cohort.17 Eligible subjects were adults 18 years of age
and older with at least one outpatient serum creatinine measurement
in the province of Alberta, Canada, between 1 May 2002 and 31
December 2006 for seven of the nine geographically based provincial
health regions, and between 1 July 2003 and 1 January 2005 and 31
December 2006, respectively, for the other two regions. To be eligible
for inclusion, patients also had to have had at least one outpatient
measure of proteinuria, as described below, but could not have been
treated with dialysis or a kidney transplant at baseline.18
Measurement of kidney function and proteinuria
We used the non-isotope dilution mass spectrometry traceable
MDRD study equation, as well as the isotope dilution mass
spectrometry-traceable MDRD study equation (Appendix), to
determine eGFR as appropriate based on the laboratory and date
of creatinine measurement. Furthermore, to reduce inter-laboratory
variation, creatinine measurements were standardized across pro-
vincial laboratories to an isotope dilution mass spectrometry
reference standard, and a laboratory-specific correction factor was
applied where necessary, as previously reported.1 Baseline kidney
function (index eGFR) was estimated using all outpatient serum
creatinine measurements taken within a 6-month period of the first
creatinine measurement, with the index eGFR defined as the mean of
the measurements in this 6-month period. The date of the last serum
creatinine measurement in the 6-month period, for individuals with
more than a single measurement, was used as the index date.17 The
size of the overall cohort permitted us to evaluate refined categories
of eGFR, with index eGFR categorized as X105, 90–104.9, 75–89.9,
60–74.9, 45–59.9, 30–44.9, and 15–29.9ml/min per 1.73m2. In
sensitivity analysis, we used the CKD-EPI equation (Appendix),
which may perform better at higher levels of true GFR.19
Outpatient random spot urine measurements were used to
capture proteinuria based on a urine dipstick. We defined
proteinuria as normal (urine dipstick negative), mild (urine dipstick
trace or 1þ ), or heavy (urine dipstick X2þ ).13 All outpatient
urine dipstick measurements in the 6-month periods before and
after the index eGFR were used to establish baseline proteinuria.
Analyses used proteinuria as an ordinal variable according to these
three categories, with the median of all respective measurements
selected for each patient with multiple measurements.
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Covariates
Provincial health ministry administrative data files (Alberta Health
and Wellness) were used to define demographic characteristics and
comorbid conditions. Aboriginal race/ethnicity was determined
from First Nations status in the registry file. Socioeconomic status
was categorized as high income (annual adjusted taxable family
income X$39,250 CAD), low income (annual adjusted taxable
family income o$39,250 CAD), and low income with subsidy
(receiving social assistance) based on government records.20
Diabetes mellitus and hypertension were identified from hospital
discharge records and physician claims based on validated
algorithms.21,22 Other comorbid conditions were identified using
validated ICD-9-CM and ICD-10 coding algorithms applied to
physician claims and hospitalization data.23 The presence of one or
more diagnostic code in any position up to 3 years before cohort
entry was used for identification of comorbidities.
Ascertainment of outcomes
Patients were followed up from their index date until the end
of the study (31 March 2007). The primary outcome of interest was
all-cause mortality, as identified from the Alberta Health and
Wellness Registry file. Secondary outcomes were first hospitalization
for acute myocardial infarction,24 first hospitalization for stroke or
transient ischemic attack,25 occurrence of end-stage renal disease,
defined as the date of registration for chronic dialysis or renal
transplantation,26 and the occurrence of an outpatient serum
creatinine measurement that was twice as high as the first creatinine
measurement during the study period (corresponding to a 50%
decline in kidney function), assessed at the end of follow-up. We
also considered the outcome of a fourfold increase in serum
creatinine, defined using similar methods.
Statistical analyses
Multivariable Cox proportional hazards regression was used
to evaluate the association between eGFR categories and each of
the outcomes of interest, with output expressed as hazard
ratios with 95% confidence intervals, and adjusted for the socio-
demographic variables and comorbidities listed in Table 1 as per
our a priori analysis plan. The referent category for these analyses
was the intersection category of eGFR 60–74.9ml/min per
1.73m2 and normal proteinuria; for the overall results, the referent
category was eGFR 60–74.9ml/min per 1.73m2. The proportional
hazard assumption for the Cox models was tested and met.
Two-way interactions between eGFR and proteinuria were assessed
for all six clinical outcomes. Poisson regression was used to
calculate the absolute rates. The variable used to calculate the test
for trend in eGFR was defined by the median eGFR value in each
category; the test for trend in dipstick proteinuria was calculated
using values of 1, 2, and 3 for normal, mild, and heavy proteinuria,
respectively.27 The primary analyses included all participants.
However, because of the known relation between hyperfiltration
(high eGFR) and diabetes, we performed a sensitivity analysis
examining the association between eGFR and all-cause mortality in
which all people with diabetes were excluded. Statistical analyses
were performed using SAS version 9.2 (SAS Institute, Cary, NC) and
STATA version 10.1 (STATA, College Station, TX). A P-value of
o0.05 was used to indicate statistical significance, without
adjustment for multiple comparisons. The institutional review
boards of the Universities of Calgary and Alberta approved the
study.
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APPENDIX
MDRD estimated glomerular filtration rate (eGFR)
For males: 175 SCr(1.154) age(0.203)
For females: 175 SCr(1.154) age(0.203) 0.742
Chronic kidney disease-EPI eGFR
For males with SCrp0.9: 141 0.993(age) [SCr/0.9](0.411)
For males with SCr40.9: 144 0.993(age) [SCr/0.9](1.209)
For females with SCrp0.7: 144 0.993(age) [SCr/0.7](0.329)
For females with SCr40.7: 144 0.993(age) [SCr/0.7](1.209)
SCr (serum creatinine) in mg/dl
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